Genmab's (GMAB) $8 billion offer for Merus (MRUS) represents a "good deal" that largely reflects the
PREMIUM
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Upgrade
Already have a subscription? Sign in
Genmab's $8 Billion Bid Represents 'Good Deal' for Merus' Petosemtamab, Truist Says
Published 1 month ago
Sep 29, 2025 at 3:38 PM
Positive
Auto